scholarly journals Characteristics of Patients Experiencing Extrapyramidal Symptoms or Other Movement Disorders Related to Dopamine Receptor Blocking Agent Therapy

2019 ◽  
Vol 39 (4) ◽  
pp. 336-343 ◽  
Author(s):  
Shaina Musco ◽  
Laura Ruekert ◽  
Jaclyn Myers ◽  
Dennis Anderson ◽  
Michael Welling ◽  
...  
Keyword(s):  
Dopamine Receptor ◽  
Movement Disorders ◽  
Blocking Agent ◽  
Extrapyramidal Symptoms ◽  
Receptor Blocking

scholarly journals Manajemen Perioperatif Gejala Ekstrapiramidal (EPS) pada Hidrocephalus Tekanan Normal (NPH)

2020 ◽  
Vol 9 (2) ◽  
pp. 183-190
Author(s):  
Agus Baratha Suyasa ◽  
◽  
Ni Putu Dharmi Lestari ◽  
Keyword(s):  
Dopamine Receptor ◽  
Normal Pressure Hydrocephalus ◽  
Normal Pressure ◽  
Extrapyramidal Symptoms ◽  
Medical Rehabilitation ◽  
Long Term Results ◽  
Shunt Operation ◽  
Receptor Blocking

Extrapyramidal symptoms (EPS) are movement disorders due to side effects of dopamine receptor blocking agents. Symptoms of EPS include dystonia, akathisia, and parkinsonism. Symptoms of EPS in this case are found in normal pressure hydrocephalus (NPH) which does not consume dopamine receptor blocking drugs. Normal pressure hydrocephalus is hydrocephalus which does not coincide with intracranial pressure (ICT) elevation. Reported a case of a 57-year-old male with decreased consciousness and extrapyramidal symptoms and Normo pressure hydrocephalus (NPH), a V-P Shunt operation was performed. The operation was carried out under general anesthesia, using a non-kinking ETT no. 7.5, controlled ventilation. Premedication given midazolam 2 mg iv, Co induction with oxycodon 10 mg iv. Induction with propofol 150 mg iv, intubation facilities with rocketuronium 30 mg iv, maintenance with O2: Air (50: 50), sevoflurane, propofol continuous 100 mg/hour, rokuronium 20 mg/hour. Stable hemodynamics, SBP 130–150 mmHg, DBP 80–90 mmHg, HR 50–70 x/min, O2 saturation 99–100%, etCO2 35–37. After surgery the patient was treated in the intensive care unit (ICU) for monitoring blood pressure and extrapyramidal symptoms. The main goal of treatment should not be solely for the treatment of acute symptoms of EPS but also for the management of basic disease causing EPS related to morbidity and maintaining quality of life. Multidisciplinary management (neurosurgery, neurosurgery, intensive anesthesia and medical rehabilitation) are needed for better long-term results.

scholarly journals Dopamine-receptor blocking agent-associated akathisia: a summary of current understanding and proposal for a rational approach to treatment

2020 ◽  
Vol 10 ◽  
pp. 204512532093757
Author(s):  
Shaina Musco ◽  
Vivian McAllister ◽  
Ian Caudle
Keyword(s):  
Dopamine Receptor ◽  
Blocking Agent ◽  
Population Based ◽  
Rational Approach ◽  
Receptor Blocking ◽  
Serotonergic Receptors ◽  
Vulnerable Patient ◽  
The Subject ◽  
Dopamine Signaling ◽  
The Brain

Dopamine-receptor blocking agent-associated akathisia (DRBA-A) is an adverse effect that can significantly limit the use of these important medications for the treatment of a variety of psychiatric diseases, yet there is no unifying theory regarding its pathophysiology. This knowledge gap limits clinicians’ ability to effectively manage DRBA-A and mitigate negative outcomes in an already vulnerable patient population. Based on a review of the current literature on the subject, it is hypothesized that dopaminergic and noradrenergic signaling is perturbed in DRBA-A. Accordingly, it is proposed that the optimal agent to manage this extrapyramidal symptom should increase dopamine signaling in the affected areas of the brain and counteract compensatory noradrenergic signaling via antagonism of adrenergic or serotonergic receptors.

Hyperprolactinaemia and DNA synthesis in the pituitary gland of the rat

1983 ◽  
Vol 97 (1) ◽  
pp. 65-74 ◽  
Author(s):  
J. A. Burdman ◽  
M. T. Calabrese ◽  
R. M. MacLeod
Keyword(s):  
Dna Synthesis ◽  
Pituitary Gland ◽  
Dopamine Receptor ◽  
Dna Content ◽  
Anterior Pituitary ◽  
Blocking Agent ◽  
Anterior Pituitary Gland ◽  
Host Animal ◽  
Receptor Blocking ◽  
Tumour Bearing

Hyperprolactinaemia produced in rats by the transplanted prolactin-secreting tumours MtTW15 and 7315a significantly (P<0·01) inhibited by 70% the incorporation of [3H]thymidine into the pituitary DNA of the host animals. The weight and the DNA content of the glands were significantly (P<0·01) reduced by 30%. The administration of haloperidol, a dopamine receptor blocking agent, to the tumour-bearing rats increased the suppressed DNA replication in the anterior pituitary glands by approximately 560% in the MtTW15-bearing rat and by 100% in the 7315a-bearing animals. Furthermore, injection of drugs which stimulate prolactin release either by blocking the synthesis of dopamine (α-methyl-p-tyrosine) or the re-uptake of dopamine (reserpine) stimulated DNA synthesis by 800 and 100% respectively in the anterior pituitary gland of rats bearing the MtTW15 tumour. In contrast, lisuride, a dopamine agonist, significantly inhibited the incorporation of [3H]thymidine into the DNA of the pituitary gland of normal but not hyperprolactinaemic rats. Chronically administered oestrogens to hyperprolactinaemic rats increased the weight (100%), DNA content (31%), incorporation of [3H]thymidine into DNA (680%) and synthesis and release of prolactin (300%) in the pituitary gland. The incorporation of [3H]thymidine into tumour DNA was several times higher than in the pituitary gland of the host animal and was not significantly modified by any of the above treatments. Likewise the hyperprolactinaemia of the tumour-bearing rats was not significantly changed. In conclusion, we have shown that hyperprolactinaemia inhibits DNA synthesis in the anterior pituitary gland and this inhibition can be reversed completely by a dopamine receptor blocking agent and by hypothalamic dopamine depleting drugs. We propose that dopamine regulates, either directly or indirectly, DNA synthesis in the lactotrophs of the pituitary gland, which may be responsive to negative feedback mechanisms.

Pulsatile Growth Hormone and Prolactin: Effects of (+) Butaclamol, a Dopamine Receptor Blocking Agent

Endocrinology ◽  
1977 ◽  
Vol 101 (4) ◽  
pp. 1298-1303 ◽  
Author(s):  
J. O. WILLOUGHBY ◽  
P. BRAZEAU ◽  
J. B. MARTIN
Keyword(s):  
Growth Hormone ◽  
Dopamine Receptor ◽  
Blocking Agent ◽  
Receptor Blocking

Recognition of Movement Disorders in Psychiatry: Video Fragments

2009 ◽  
Vol 24 (S1) ◽  
pp. 1-1
Author(s):  
P.N. van Harten ◽  
H.W. Hoek
Keyword(s):  
Tardive Dyskinesia ◽  
Dopamine Receptor ◽  
Movement Disorders ◽  
Clinical Aspects ◽  
Drug Induced ◽  
Receptor Blocking ◽  
Tardive Dystonia ◽  
Blocking Agents ◽  
Somatic Disease ◽  
Psychiatric Syndrome

Movement disorders in psychiatry can be divided in those related to an underlying neurological or other somatic disease, related to a psychiatric syndrome, drug induced and psychogenic. In this workshop the typical clinical aspects of each of these movement disorders will be discussed and shown on video with the focus on drug induced. Drug induced can be divided in acute and tardive movement disorders. Acute movement disorders such as acute dystonia, akathisia, parkinsonism and mycoclonus, start short after taking dopamine receptor blocking agents, often an antipsychotic. Once recognized they are relatively easy to treat. Tardive movement disorders such as tardive dyskinesia and tardive dystonia start months or years after using dopamine receptor blocking agents. Treatment is often disappointing, therefore prevention is needed.

scholarly journals Preventing Broodiness in Turkey Hens with a Dopamine Receptor Blocking Agent

1980 ◽  
Vol 59 (5) ◽  
pp. 1126-1131 ◽  
Author(s):  
J.R. MILLAM ◽  
W.H. BURKE ◽  
M.E. El HALAWANI ◽  
L.A. OGREN
Keyword(s):  
Dopamine Receptor ◽  
Blocking Agent ◽  
Receptor Blocking
Sign in / Sign up

Export Citation Format

Share Document